|Videos|June 15, 2022
A US-Based, Injectables-Focused CDMO with Available Capacity and End-to-End Capabilities
Author(s)August Bioservices
Ryan Downey, Director of Customer Operations, outlines August Bioservices’ capabilities for its customers and what it means to work with them.
- They focus on sterile injectables in multiple container sizes from vials to syringes to flexible IV bags— coupled with an analytical services department.
- The current CDMO market is constrained for those who need the capacity to start their innovative work, which is where August Bioservices comes in.
- With robust tools and a strong team, they can solve difficult challenges with formulation, commercial configuration, the timing of a project, and analytical characterizations.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
Trending on Pharmaceutical Technology
1
Lilly Invests $3.5B in Pennsylvania Injectable Medicine Facility
2
Navigating the Complex Risks of Accelerated Pharmaceutical Launches
3
Securing Radiopharma and GLP-1 Supply Chains Through 2026 M&A
4
Repertoire Immune Medicines and Lilly Collaborate on Treatments for Autoimmune Diseases
5